Compare Abeona Therapeutics Inc (ABEO) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Qurate Retail Inc Series A — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Qurate Retail Inc Series A trades at $0.08 (market cap $1.12M). The key difference: Abeona Therapeutics Inc is far larger — about 333.3× Qurate Retail Inc Series A's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| ABEO | QVCAQ | |
|---|---|---|
Market Cap | $373.32M | $1.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $15.03 |
52-Week Low | $4.17 | $0.07 |
Enterprise Value | $228.22M | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QVCAQ trades at $0.109, up 37.97% in 24 hours, but technical signals are bearish with 13 sell signals on moving averages. The company reported a net loss of $2.44 billion in 2025, with negative shareholder equity of $971 million and a debt-to-asset ratio of 77.57%. Recent news highlights QVC's 40th anniversary and TikTok Shop partnership (PRNewsWire, 2026-05-28).
The outlook remains highly speculative due to persistent losses, negative equity, and high leverage. Risks include financial distress and competitive pressures, while any positive sentiment hinges on operational turnarounds. Investors should approach with caution given the fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
